logo

For the Inventor, By the Inventor

Jena, Germany

Inflarx Gmbh

Calculating rank
USPTO Granted Patents = 14



Trademarks = 2

Forward Citations = 64

Loading Chart...
Loading Chart...

8 inventors (with patents filed for the assignee):

goldMedal Renfeng Guo (14 out of 15 patents)

silverMedal Niels Christoph Riedemann (12 out of 12 patents)

bronzeMedal Beifen Shen (4 out of 7 patents)

4.  Yan Li (3 out of 308 patents)

5.  Yong Li (2 out of 2 patents)

6.  Niels R Riedemann (1 out of 1 patent)

7.  Niels Cristoph Riedemann (1 out of 1 patent)

8.  Yan Li (1 out of 2 patents)

9.  Li Yan (0 patent)

10.  Yan Li (0 patent)

11.  Shen Beifen (0 patent)


14 patents:

1. 12697351 - METHOD OF TREATING CONDITIONS, REDUCING AN INFLAMMATORY RESPONSE, OR IMPROVING ORGAN FUNCTION IN A SUBJECT HAVING A CORONA VIRUS INFECTION BY ADMINISTERING AN INHIBITOR OF C5A ACTIVITY (2026-08-04),
2. 12180274 - Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity (2024-12-31),
3. 11999698 - Fused piperidinyl bicyclic and related compounds as modulators of C5a receptor (2024-06-04),
4. 11890349 - Treatment of inflammatory diseases with inhibitors of C5A activity (2024-02-06),
5. 11464868 - Treatment of inflammatory diseases with inhibitors of C5A activity (2022-10-11),
6. 11273225 - Treatment of inflammatory diseases with inhibitors of C5a activity (2022-03-15),
7. 11149009 - Fused piperidinyl bicyclic and related compounds as modulators of C5A receptor (2021-10-19),
8. 10858421 - Inhibitors of C5A for the treatment of viral pneumonia (2020-12-08),
9. 10774136 - Anti-C5a binding moieties with high blocking activity (2020-09-15),
10. 10376595 - Treatment of inflammatory diseases with inhibitors of C5a activity (2019-08-13),
11. 10227397 - Inhibitors of C5a for the treatment of viral pneumonia (2019-03-12),
12. 9458233 - Anti-C5a binding moieties with high blocking activity (2016-10-04),
13. 9073983 - Anti-C5A binding moieties with high blocking activity (2015-07-07),
14. 8802096 - Anti-C5a binding antibodies with high block activity (2014-08-12),
Company Overview
Inflarx GmbH is a biopharmaceutical company based in Jena, Germany, specializing in the development of innovative therapies for autoimmune and inflammatory diseases. The company focuses on harnessing its proprietary technology to create monoclonal antibodies that target specific pathways involved in these conditions. With a commitment to advancing medical science, Inflarx aims to address unmet medical needs through its research and development efforts, contributing to improved patient outcomes in the therapeutic landscape.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

14 Patents

#28 in Jena

#2,911 in Germany

#42,312 in the World

Jena, DE
Jena, Germany

Inflarx Gmbh

Forward Citations = 64

8 inventors:

goldMedal Renfeng Guo (14 out of 15 patents)

silverMedal Niels Christoph Riedemann (12 out of 12 patents)

bronzeMedal Beifen Shen (4 out of 7 patents)

4.  Yan Li (3 out of 308 patents)

5.  Yong Li (2 out of 2 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Inflarx Gmbh. Retrieved from https://idiyas.com/company/inflarx

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…